Interviews

Jonathan Friedberg, MD, MMSc, discusses results from the SWOG S1826 trial which led to the recent FDA approval of nivolumab plus doxorubicin, vinblastine, and dacarbazine for patients with advanced-stage Hodgkin lymphoma.

Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.

Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.

Alison Schram, MD, discusses the treatment course taken for a case of a patient with non-small cell lung cancer with a CD74-NRG1 gene fusion.

Srikala Sridhar, MD, discusses results from the phase 2 ALPACA study evaluating avelumab in patients with locally advanced or metastatic penile cancer who were unfit for or experienced disease progression after platinum-based chemotherapy.

Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...

Sarah Rutherford, MD, discusses recent updates in frontline treatment for patients with diffuse large B-cell lymphoma.

Erika Hamilton, MD, discusses results from the phase 3 VERITAC-2 study which revealed vepdegestrant yielded longer progression-free survival vs fulvestrant among patients with ER-positive, HER2-negative advanced breast cancer and an ESR1...

Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.

Juan Gimenez, MD, discusses the implications of a recent analysis of yttrium-90 (Y-90) glass microsphere radioembolization for interventional radiology.